2023-03-24 07:23:35 ET
- ATAI Life Sciences press release ( NASDAQ: ATAI ): Q4 GAAP EPS of -$0.28 misses by $0.05 .
- Revenue of $0.04M (-82.6% Y/Y) misses by $0.07M .
- Cash and cash equivalents and short-term investments were $273.1 million as of December 31, 2022, as compared to $362.3 million as of December 31, 2021.
- The Company expects its cash position, combined with access to up to $160M in additional capital from its term loan facility with Hercules Capital, Inc., will be sufficient to fund operations into 1H 2026.
For further details see:
ATAI Life Sciences GAAP EPS of -$0.28 misses by $0.05, revenue of $0.04M misses by $0.07M